Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC)

Ashique S 1 , Garg A 2 , Mishra N 3 , Raina N 4 , Ming LC 5 , Tulli HS 6 Show all authors , Behl T 7 , Rani R 4 , Gupta M 8

Affiliations 

  • 1 Department of Pharmaceutics, Bharat Institute of Technology (BIT), School of Pharmacy, Meerut, 250103, UP, India
  • 2 Department of Pharmaceutics, Guru Ramdas Khalsa Institute of Science and Technology, Jabalpur, M.P, 483001, India
  • 3 Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, 474005, MP, India
  • 4 Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, PushpVihar, New Delhi, 110017, India
  • 5 Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, Indonesia
  • 6 Department of Biotechnology, Maharishi Markandeshwar Engineering College, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala, 133207, India
  • 7 School of Health Sciences and Technology, University of Petroleum and Energy Studies, Bidholi, Dehradun, India
  • 8 Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, PushpVihar, New Delhi, 110017, India. madhugupta98@gmail.com
Naunyn Schmiedebergs Arch Pharmacol, 2023 Nov;396(11):2769-2792.
PMID: 37219615 DOI: 10.1007/s00210-023-02522-5

Abstract

Lung cancer is the most common type of cancer, with over 2.1 million cases diagnosed annually worldwide. It has a high incidence and mortality rate, leading to extensive research into various treatment options, including the use of nanomaterial-based carriers for drug delivery. With regard to cancer treatment, the distinct biological and physico-chemical features of nano-structures have acquired considerable impetus as drug delivery system (DDS) for delivering medication combinations or combining diagnostics and targeted therapy. This review focuses on the use of nanomedicine-based drug delivery systems in the treatment of lung cancer, including the use of lipid, polymer, and carbon-based nanomaterials for traditional therapies such as chemotherapy, radiotherapy, and phototherapy. The review also discusses the potential of stimuli-responsive nanomaterials for drug delivery in lung cancer, and the limitations and opportunities for improving the design of nano-based materials for the treatment of non-small cell lung cancer (NSCLC).

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications